GLY-200 is under clinical development by Glyscend and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GLY-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GLY-200 overview
GLY-200 is under development for the treatment of type 2 diabetes and obesity. It is administered by oral route. It is being developed based on polymer technology.
Glyscend overview
Glyscend., is a developer of approach to treating type 2 diabetes. The company is headquartered in United States.
For a complete picture of GLY-200’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.